100 related articles for article (PubMed ID: 8429690)
1. Effects of interleukin 2 on myelodysplastic syndromes.
Ogata K; Yokose N; Ito T; An E; Dan K; Nomura T
Leuk Res; 1993 Feb; 17(2):137-42. PubMed ID: 8429690
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
Ogata K; Yokose N; Nomura T
Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
[TBL] [Abstract][Full Text] [Related]
3. In vitro IL-12 treatment of peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes: increase in cytotoxicity and reduction in WT1 gene expression.
Pan L; Ohnishi K; Zhang WJ; Yoshida H; Maksumova L; Muratkhodjaev F; Shigeno K; Nakamura S; Luo JM; Hao HL; Fujisawa S; Naito K; Shinjo K; Takeshita A; Ohno R
Leukemia; 2000 Sep; 14(9):1634-41. PubMed ID: 10995011
[TBL] [Abstract][Full Text] [Related]
4. Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes.
Ogata K; Yokose N; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T
Br J Haematol; 1994 Mar; 86(3):562-7. PubMed ID: 8043438
[TBL] [Abstract][Full Text] [Related]
5. In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.
Cortelezzi A; Sarina B; Cattaneo C; Pomati M; Silvestris I; Soligo D; Calori R; Di Stefano M; Hu C; Monza M; Radelli L; Maiolo AT
Leukemia; 1996 Jul; 10(7):1181-9. PubMed ID: 8684000
[TBL] [Abstract][Full Text] [Related]
6. Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes.
Ogata K; Tamura H; Yokose N; An E; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Clark SC; Nomura T
Br J Haematol; 1995 May; 90(1):15-21. PubMed ID: 7786778
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS).
Sarina B; Cortelezzi A; Cattaneo C; Pomati M; Silvestris I; Di Stefano M; Lambertenghi-Deliliers D; Hu C; Monza M; Maiolo AT
Leukemia; 1997 Oct; 11(10):1726-31. PubMed ID: 9324294
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of lymphocyte lectin-dependent cytotoxicity in myelodysplastic syndromes.
Fontana L; De Sanctis G; De Rossi G; Bottari V; Petti MC; Ensoli F; Pasqualetti D; Mandelli F
Acta Haematol; 1989; 82(1):1-6. PubMed ID: 2505468
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
10. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
Kiladjian JJ; Visentin G; Viey E; Chevret S; Eclache V; Stirnemann J; Bourhis JH; Chouaib S; Fenaux P; Caignard A
Haematologica; 2008 Mar; 93(3):381-9. PubMed ID: 18268282
[TBL] [Abstract][Full Text] [Related]
11. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.
Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W
Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679
[TBL] [Abstract][Full Text] [Related]
12. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.
Bamford RN; Grant AJ; Burton JD; Peters C; Kurys G; Goldman CK; Brennan J; Roessler E; Waldmann TA
Proc Natl Acad Sci U S A; 1994 May; 91(11):4940-4. PubMed ID: 8197161
[TBL] [Abstract][Full Text] [Related]
13. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
14. IL-12 and IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients.
Verma V; Sharma V; Shrivastava SK; Nadkarni JJ
J Exp Clin Cancer Res; 2000 Sep; 19(3):367-74. PubMed ID: 11144531
[TBL] [Abstract][Full Text] [Related]
15. Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome.
Cukrová V; Neuwirtová R; Dolezalová L; Belicková M; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
Exp Hematol; 2009 Mar; 37(3):386-94. PubMed ID: 19136196
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte interleukin 2 production and responsiveness are altered in patients with primary myelodysplastic syndrome.
Ayanlar-Batuman O; Shevitz J; Traub UC; Murphy S; Sajewski D
Blood; 1987 Aug; 70(2):494-500. PubMed ID: 2955819
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of interleukin 10 on interleukin 12- and interleukin 2-mediated killer induction from blood mononuclear cells.
Pai K; Yanagawa H; Takauchi E; Suzuki Y; Hanibuchi M; Parajuli P; Sone S
Oncol Res; 1998; 10(6):295-300. PubMed ID: 9848100
[TBL] [Abstract][Full Text] [Related]
18. Effects of herpes simplex virus on induced cell-mediated cytotoxicity in neonates and adults.
Chin TW; Plaeger-Marshall S; Ank BJ; Pressman SR; Stiehm ER
Nat Immun Cell Growth Regul; 1991; 10(5):237-46. PubMed ID: 1661847
[TBL] [Abstract][Full Text] [Related]
19. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
20. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
